01 Nov, 2022 RNAi Roundtable: CNS Delivery and ALN-APP, an Investigational RNAi Therapeutic in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
On November 1, 2022, we hosted an online RNAi roundtable to review Alnylam’s CNS delivery platform and ALN-APP, an investigational RNAi therapeutic in development for Alzheimer’s Disease and cerebral amyloid angiopathy.
Senior Vice President, Development Programs
Kirk Brown, Ph.D.
Senior Director, Research, CNS Program
Director, Program Leader, ALN-APP Program